DENVER--(BUSINESS WIRE)--June 27, 2006--Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced that it has received Institutional Review Board (IRB) approval to commence a multicenter study involving 90 children, aged 6 months to 18 years, with moderate-to-severe atopic dermatitis (eczema). The study, which is expected to commence in July of this year and take place at private dermatology offices located in Santa Rosa, California and Trenton, New Jersey, will compare the use of EpiCeram®, a non-steroidal skin barrier cream that received FDA marketing clearance in April 2006, to Cutivate®, a commonly used mid-strength topical steroid that is approved for use in infants and children.
